

2026 MSTCVS Value-Based Reimbursement General Thoracic Surgery



Measures 1-4 are collaborative wide
The target must be achieved at the collaborative level in 3 of 4 measures (1 - 4) or
at the hospital level in 4 of 4 measures (1-4) to receive reimbursement.

	Statewide Measure Description	Measurement Period	Baseline State Mean	Statewide Target Performance
1	Pathologic sampling of 3 mediastinal and 1 hilar lymph node stations at the time of lung cancer resection (Lobectomy, segmentectomy, pneumonectomy, therapeutic wedge resection)	1/1/26-9/30/26	82%	≥ 84%
2	Decrease number of days from surgeon consult to therapeutic lung resection for patients with clinical stage ≤T1N0 (Lobectomy, segmentectomy, pneumonectomy, therapeutic wedge resection)	1/1/26-9/30/26	32.3 Days	≤ 28 Days
3	Increase brain imaging for patients with clinical stage II-IIIa non-small cell lung cancer (Lobectomy, segmentectomy, pneumonectomy, therapeutic wedge resection)	1/1/26-9/30/26	69%	≥ 75%
4	Invasive mediastinal staging for patients with clinical stage ≥T2N0 non-small cell lung cancer (Lobectomy, segmentectomy, pneumonectomy, therapeutic wedge resection)	1/1/26-9/30/26	75.6%	≥ 82%
5	Surgeon and Data Manager participation in quarterly Collaborative meetings <i>*site-specific opportunity for General Thoracic only participants</i>	1/1/26-9/30/26	NA	*2 out of 3 meetings (February/April/August)